NRX Pharmaceuticals Inc • NRXP

Capital at risk.

About NRX Pharmaceuticals Inc
Ticker
info
NRXP
Trading on
info
NASDAQ
ISIN
info
US6294442099
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Jonathan C. Javitt M.D., M.P.H.
Headquarters
info
1201 Orange Street, Wilmington, DE, United States, 19801
Employees
info
0
Website
info
nrxpharma.com
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Metrics
BasicAdvanced
Market cap
info
$67.7M
P/E ratio
info
-
EPS
info
-$2.31
Dividend Yield
info
0.00%
Beta
info
1.9
Forward P/E ratio
info
9.64
EBIDTA
info
$-15.2M
Ex dividend date
info
-
Price & volume
Market cap
info
$67.7M
Average daily volume
info
0.4M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
9.64
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
279.82
Price to book
info
2.9
Earnings
EPS
info
-$2.31
EPS estimate (current quarter)
info
-$0.02
EPS estimate (next quarter)
info
$0.09
EBITDA
info
$-15.2M
Revenues (TTM)
info
$0.2M
Revenues per share (TTM)
info
$0.01
Technicals
Beta
info
1.9
52-week High
info
$6.01
52-week Low
info
$1.15
50-day moving average
info
$2.86
200-day moving average
info
$2.65
Short ratio
info
3.01
Short %
info
5.16%
Management effectiveness
ROE (TTM)
info
-682.61%
ROA (TTM)
info
-97.83%
Profit margin
info
0.00%
Gross profit margin
info
$0.1M
Operating margin
info
-1,701.65%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
28.1M
Float
info
20.3M
Insiders %
info
9.77%
Institutions %
info
25.06%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 3 analysts.

Average price target

info
$36.50
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.77
-$0.37
-108.11%
Q4 • 24Missed
-$0.34
-$0.53
35.85%
Q1 • 25Beat
-$0.98
-$0.53
-84.91%
Q2 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-17.6M
-∞%
Q2 • 25
$0.2M
$-5.9M
-2,433.88%
Q3 • 25
∞%
-66.50%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$4.8M
$40.5M
836.15%
Q2 • 25
$15M
$40.8M
271.75%
Q3 • 25
209.96%
0.74%
-67.50%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-4M
-
$1.4M
$-4M
Q2 • 25
$-2.9M
-
$9.7M
$-2.9M
Q3 • 25
-28.23%
-
599.71%
-28.23%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a NRX Pharmaceuticals Inc share?
Collapse

NRX Pharmaceuticals Inc shares are currently traded for undefined per share.

How many shares does NRX Pharmaceuticals Inc have?
Collapse

NRX Pharmaceuticals Inc currently has 28.1M shares.

Does NRX Pharmaceuticals Inc pay dividends?
Collapse

No, NRX Pharmaceuticals Inc doesn't pay dividends.

What is NRX Pharmaceuticals Inc 52 week high?
Collapse

NRX Pharmaceuticals Inc 52 week high is $6.01.

What is NRX Pharmaceuticals Inc 52 week low?
Collapse

NRX Pharmaceuticals Inc 52 week low is $1.15.

What is the 200-day moving average of NRX Pharmaceuticals Inc?
Collapse

NRX Pharmaceuticals Inc 200-day moving average is $2.65.

Who is NRX Pharmaceuticals Inc CEO?
Collapse

The CEO of NRX Pharmaceuticals Inc is Dr. Jonathan C. Javitt M.D., M.P.H..

How many employees NRX Pharmaceuticals Inc has?
Collapse

NRX Pharmaceuticals Inc has 0 employees.

What is the market cap of NRX Pharmaceuticals Inc?
Collapse

The market cap of NRX Pharmaceuticals Inc is $67.7M.

What is the P/E of NRX Pharmaceuticals Inc?
Collapse

The current P/E of NRX Pharmaceuticals Inc is null.

What is the EPS of NRX Pharmaceuticals Inc?
Collapse

The EPS of NRX Pharmaceuticals Inc is -$2.31.

What is the PEG Ratio of NRX Pharmaceuticals Inc?
Collapse

The PEG Ratio of NRX Pharmaceuticals Inc is null.

What do analysts say about NRX Pharmaceuticals Inc?
Collapse

According to the analysts NRX Pharmaceuticals Inc is considered a buy.